Leflunomide-induced acute hepatitis

被引：40

作者：

Sevilla-Mantilla, C

Ortega, L

Agúndez, JAG

Fernández-Gutiérrez, B

Ladero, JM

Díaz-Rubio, M

机构：

[1] Univ Complutense Madrid, Gastroenterol Serv, Hosp Clin San Carlos, E-28040 Madrid, Spain

[2] Univ Complutense Madrid, Hosp Clin San Carlos, Serv Pathol, Madrid, Spain

[3] Univ Extremadura, Dept Pharmacol, Badajoz, Spain

[4] Univ Complutense Madrid, Hosp Clin San Carlos, Serv Rheumatol, Madrid, Spain

来源：

DIGESTIVE AND LIVER DISEASE | 2004年 / 36卷 / 01期

关键词：

CYP2C9; genetic polymorphism; leflunomide;

D O I：

10.1016/j.dld.2003.06.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Leflunomide, a new immunomodulatory agent, was prescribed to a 67-year-old female patient with rheumatoid arthritis. Fifteen days later she developed diarrhoea and elevated liver enzymes. A liver biopsy showed a pattern of acute hepatitis. The patient was homozygous for the rare CYP2C9*3 allele, which determines the slowest metabolic rate for CYP2C9 enzymatic activity, that is probably involved in the metabolism of leflunomide. Liver damage subsided in few weeks. This case illustrates the risk of hepatotoxicity by leflunomide and suggests that it is possibly related to CYP2C9 polymorphism. (C) 2003 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

引用

收藏

页码：82 / 84

页数：3

相关论文

共 17 条

[1] A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis [J].

Emery, P ;

Breedveld, FC ;

Lemmel, EM ;

Kaltwasser, JP ;

Dawes, PT ;

Gömör, B ;

Van den Bosch, F ;

Nordström, D ;

Bjorneboe, O ;

Dahl, R ;

Horslev-Petersen, K ;

de la Serna, AR ;

Molloy, M ;

Tikly, M ;

Oed, C ;

Rosenburg, R ;

Loew-Friedrich, I .

RHEUMATOLOGY, 2000, 39 (06) :655-665

[2] High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population [J].

García-Martín, E ;

Martínez, C ;

Ladero, JM ;

Gamito, FJG ;

Agúndez, JAG .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :47-49

[3]

Gonzalez Perez J A, 1990, An Med Interna, V7, P477

[4] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms [J].

Haining, RL ;

Hunter, AP ;

Veronese, ME ;

Trager, WF ;

Rettie, AE .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) :447-458

[5] Epidemiology and individual susceptibility to adverse drug reactions affecting the liver [J].

Larrey, D .

SEMINARS IN LIVER DISEASE, 2002, 22 (02) :145-155

[6] Fatal hepatitis with leflunomide and itraconazole [J].

Legras, A ;

Bergemer-Fouquet, AM ;

Jonville-Bera, AP .

AMERICAN JOURNAL OF MEDICINE, 2002, 113 (04) :352-353

[7]

MATTESON E, REPORTS LEFLUNOMIDE

[8] Leflunomide - A review of its use in active rheumatoid arthritis [J].

Prakash, A ;

Jarvis, B .

DRUGS, 1999, 58 (06) :1137-1164

[9] Clinical pharmacokinetics of leflunomide [J].

Rozman, B .

CLINICAL PHARMACOKINETICS, 2002, 41 (06) :421-430

[10] Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine [J].

Scott, DL ;

Smolen, JS ;

Kalden, JR ;

van de Putte, LBA ;

Larsen, A ;

Kvien, TK ;

Schattenkirchner, M ;

Nash, P ;

Oed, C ;

Loew-Friedrich, I .

ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (10) :913-923